Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care?

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 4, 2015, Pages 405-407

  Watkins, Richard R ^a,b   Deresinski, Stan ^c  

^a Northeast Ohio Medical University   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carbapenem resistant Klebsiella pneumoniae; combination antibiotic therapy

Indexed keywords

CARBAPENEM; COLISTIN; DORIPENEM; ERTAPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE INFECTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; DRUG COMBINATION; DRUG EFFECTS; GENETICS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTILIZATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG THERAPY, COMBINATION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84924733307     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1018825     Document Type: Review

References (17)

1. Akova M,Daikos GL,Tzouvelekis L,et al., Interventional strategies and current clinical experience with carbapenem ase-producing Gram-negative bacteria, Clin Microbiol Infect, 2012, 18, 439-48.
2. Petrosillo N, Giannella M, Lewis R, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013;11: 159-77
3. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999;11:7-12
4. Timsit JF, Soubirou JF, Voiriot G, et al. Treatment of bloodstream infections in ICUs. BMC Infect Dis 2014;14:489
5. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 2012;25:450-70
6. Robilotti E, Deresinski S. Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Reports 2014;6:80
7. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrob ial regimens. Antimicrob Agents Chemother 2012;56:2108-13
8. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenem ase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50
9. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322-8
10. Durovskaya Y, Chen TY, Scipione MR, et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. A ntimicrob Agents Chemother 2013;57:5394-7
11. Demiraslan H, Dinc G, Ahmed SS, et al. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monother apy versus tigecycline/colistin combination. J Chemother 2014;26:276-81
12. Wiskirchen DE, Crandon JL, Nicolau DP. Impact on various conditions on the efficacy of dual carbapenem therapy against KPC -producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013;41:582-5
13. Lamoureaux TL, Frase H, Antunes NT, et al. Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6. Antimicrob Agents Chemother 2012;56:6006-8
14. Watkins RR, Papp-Wallace KM, Drawz SM, et al. Novel b-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol 2013;4:392
15. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/b-lactamase inhibitor combination. Drugs 2013;73:159-77.
16. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69: 2305-9
17. Modi SR, C ollins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest 2014;124:4212-18